Ohm Laboratories gets FDA warning for manufacturing issues

12/27/2009 | Wall Street Journal, The

Ohm Laboratories, a unit of Indian drug firm Ranbaxy Laboratories, received a warning letter from the FDA regarding manufacturing violations at a Gloversville, N.Y., facility. Ranbaxy said the agency "did not observe any material deviation" in the unit's other facilities in the U.S. and that it plans to cooperate with the agency.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX